title: Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH).
abstract: Androgen effects on lipoproteins, mainly high density lipoprotein (HDL), could be exerted by a direct interaction of testosterone (T) or dihydrotestosterone (DHT) with liver androgen receptors. To assess if T needs to be converted into DHT to affect lipid metabolism, 13 patients were studied, affected with benign prostatic hyperplasia (BPH) and treated with an inhibitor of 5 alpha-reductase (finasteride). They were compared with 15 untreated controls. At baseline and after 3 and 6 months of therapy, each patient was evaluated as for lipoprotein and hormone concentrations, as well as for nutritional status. Body composition was assessed by anthropometry and bio-impedance analysis (BIA). Treatment was associated with a significant increase of HDL-cholesterol (HDL-C), mainly HDL3 subclass, and lipoprotein(a) (Lp(a)), as well as a decline of DHT, whereas no significant changes were apparent for T, estradiol (E2), sex hormone binding hormone (SHBG) and body composition indexes. However, no significant associations between DHT and lipid relative changes were apparent at bivariate correlation analysis. This finding was confirmed by comparing patient subsets identified by cluster analysis, according to HDL subclass individual responses. Rather, a slight association with E2 for HDL2 (positive) and HDL3 (negative) was found. In conclusion, finasteride can modify HDL and Lp(a) concentrations. However, by the data, these effects cannot be definitively attributed to the changes in DHT synthesis induced by finasteride, since a direct and non-specific interference of the drug on liver metabolism cannot be excluded.
authors.affiliation: Department of Geriatrics, Cattedra di Gerontologia e Geriatria, Università di Parma, Via Don Bosco 2, 43100, Parma, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Denti
authors.forename: G
authors.initials: G
authors.lastname: Pasolini
authors.forename: P
authors.initials: P
authors.lastname: Cortellini
authors.forename: L
authors.initials: L
authors.lastname: Sanfelici
authors.forename: R
authors.initials: R
authors.lastname: Benedetti
authors.forename: A
authors.initials: A
authors.lastname: Cecchetti
authors.forename: S
authors.initials: S
authors.lastname: Ferretti
authors.forename: L
authors.initials: L
authors.lastname: Bruschieri
authors.forename: F
authors.initials: F
authors.lastname: Ablondi
authors.forename: G
authors.initials: G
authors.lastname: Valenti
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004797:Enzyme-Linked Immunosorbent Assay; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D012016:Reference Values
chemical_list: D008076:Cholesterol, HDL; D004791:Enzyme Inhibitors; D017270:Lipoprotein(a); D018120:Finasteride